Paraparesia espástica tropical en paciente autóctona / Tropical spastic paraparesis in autochthon patient

No disponible

Myelopathy due to human T-cell leukemia virus type-1 from the donor after ABO-incompatible liver transplantation.

We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukemia virus type-1 (HTLV-1) and the recipient was seronegative for HTLV-1 before transplantation. After transplantation, the recipient developed steroid-resistant acute cellular rejection, which was successfully treated using anti-thymocyte globulin, and he was eventually discharged. He underwent spinal surgery twice after the transplantation for the treatment of cervical spondylosis that had been present for a period of 9 months before the transplantation. The surgery improved his gait impairment temporarily. However, his gait impairment progressed, and magnetic resonance imaging revealed multiple sites of myelopathy. He was diagnosed with HAM 16 months after the transplantation. Pulse steroid therapy (1000mg) was administered over a period of 3 days, and his limb paresis improved. Presently, steroid therapy is being continued, with a plan to eventually taper the dose, and he is being carefully followed up at our institution. Our case suggests that liver transplantation involving an HTLV-1-positive living donor carries the risk of virus transmission and short-term development of HAM after transplantation.

Silent dissemination of HTLV-1 in an endemic area of Argentina. Epidemiological and molecular evidence of intrafamilial transmission.

BACKGROUND: Molecular and epidemiological studies of transmission routes and risk factors for infection by HTLV-1 are extremely important in order to implement control measures, especially because of the high prevalence of HTLV-1 in several regions of the world. San Salvador de Jujuy, Northwest Argentina, is a highly endemic area for HTLV-1 and foci of tropical spastic paraparesis/HTLV-1-associated myelopathy. OBJECTIVE: To gain further insight into the role of intrafamilial transmission of HTLV-1 in a highly endemic region in Argentina. METHOD: Cross-sectional study in Northwest Argentina. Epidemiological data and blood samples were collected from 28 HTLV-1 infected subjects (index cases) and 92 close relatives/cohabitants. HTLV-1 infection was diagnosed by detection of antibodies and proviral DNA. The LTR region was sequenced and analyzed for genetic distances (VESPA software), in addition to determination and identification of polymorphisms to define HTLV-1 family signatures. RESULTS: Fifty seven of the 120 subjects enrolled had antibodies against HTLV-1 and were typified as HTLV-1 by PCR. The prevalence rate of HTLV-1 infection in family members of infected index cases was 31.52% (29/92). The infection was significantly associated with gender, age and prolonged lactation. Identity of LTR sequences and presence of polymorphisms revealed high prevalence of mother-to-child and interspousal transmission of HTLV-1 among these families. CONCLUSION: There is an ongoing and silent transmission of HTLV-1 through vertical and sexual routes within family clusters in Northwest Argentina. This evidence highlights that HTLV-1 infection should be considered as a matter of public health in Argentina, in order to introduce preventive measures as prenatal screening and breastfeeding control.

[Tropical spastic paraparesis: a report of a new case in Spain]. / Paraparesia espastica tropical: presentacion de un nuevo caso en España.

TITLE: Paraparesia espastica tropical: presentacion de un nuevo caso en España.

Os efeitos de um programa de exercícios domiciliares em pacientes com Paraparesia Espástica Tropical/Mielopatia Associada ao HTLV-1 (PET/MAH) / The effects of a home-based exercise program in Tropical Spastic Paraparesis/HTLV-1 Associated Myelopathy (TSP/HAM) patients

Os efeitos da prática de exercícios sobre a funcionalidade de indivíduos com Paraparesia Espástica Tropical/Mielopatia Associada ao HTLV-1 (PET/MAH) são desconhecidos. O objetivo deste estudo é avaliar os efeitos de um Programa de Exercícios Domiciliares (PED) e a sua taxa de adesão em indivíduos com PET/MAH. Métodos: Vinte e três participantes com o diagnóstico de PET/MAH, marcha preservada e que não praticavam exercícios há pelo menos um mês foram submetidos ao PED de 20 semanas. Os desfechos primários incluíram os escores de força muscular, contração isométrica voluntária máxima (CIVM) e comprimento muscular dos membros inferiores, dor lombar e nos membros inferiores, EDSS, Escala de Incapacidade do IPEC, Índice de Barthel e SF-36. A taxa de adesão e os eventos adversos também foram mensurados e caracterizados. Resultados: No momento da análise os pacientes foram divididos em dois grupos de acordo com o teste Timed Up and Go (TUG) (<20s vs maior ou igual 20s). O comprimento dos músculos isquiotibiais e plantiflexores, a CIVM dos membros inferiores e o componente Aspectos Sociais da SF-36 apresentaram melhora significativa no grupo TUG <20s. Os indivíduos do grupo TUG maior ou igual 20s melhoraram significativamente o componente Capacidade Funcional da SF-36. A taxa de adesão foi de 90 por cento no total e os eventos adversos, como fadiga, dor muscular e caimbras foram de intensidade leve a moderada. Discussão: Foi observada uma boa adesão ao PED, além de melhora significativa da incapacidade e da qualidade de vida dos indivíduos com PET/MAH. É possível que o grupo TUG maior ou igual 20s apresente um maior componente neurodegenerativo e, portanto, uma menor probabilidade de incremento da funcionalidade. Conclusões: O PED foi eficaz em melhorar algumas incapacidades e a qualidade de vida dos indivíduos com PET/MAH...

The effect of exercises on functioning in Tropical Spastic Paraparesis/HTLV-1 Associated Myelopathy (TSP/HAM) individuals is unknown. This study aimed to investigate the effects of a home-based exercise program and its adherence in TSP/HAM individuals. Methods: Twenty-three TSP/HAM ambulators participants that did not practice any kind of exercise for at least one month were submitted to a 20-week home-based exercise program. Primary outcomes included lower limb muscular strength scores, maximum voluntary isometric contraction (MVIC) and muscle length, low back and lower limb pain, EDSS, IPEC Disability Scale, Barthel Index and SF-36. Adherence and adverse effects were also measured and characterized.Results: At analysis the participants were divided in two groups according to Timed Up and Go Test (TUG) (<20s vs greater than or equal to 20s). Muscle length of hamstrings and ankle flexors; hip flexors and total score of lower limb MVIC and the social functioning domain in SF-36 improved significantly in TUG <20s group. The individuals in the TUG greater than or equal to 20s group improved significantly the physical functioning domain in SF-36. The total adherence to the 20-weekhome-based exercise program was 90 percent. There were mild to moderate adverse events, like fatigue, muscle soreness and cramp. Discussion: There was a very good adherence to the home-based exercise program, besidesimprovements in disabilities and quality of life in TSP/HAM participants. It is possible that TUG greater than or equal to 20s group has a worse neurodegenerative component and then a lower probability tofunctioning increments. Conclusions: The home-based exercise program was effective in improving disabilities andquality of life in individuals with TSP/HAM. Those results reinforce the need for alternative strategies to face-to-face model that improve participation of these people to rehabilitationprograms...

Conhecendo o HTLV e suas implicações no atendimento odontológico / Getting to know HTLV and their implications during dental care

Os vírus T Linfotrópico humano representam um grupo de retrovírus que possuem tropismo por linfócitos T e são transmitidos pelas vias parenteral, vertical e sexual. Foram identificados os tipos 1, 2, 3 e 4 sendo que o vírus T Linfotrópico humano -1 tem sido o mais associado ao desenvolvimento de doenças nos pacientes infectados. A estimativa global é de que 15 a 20 milhões de pessoas estejam infectadas pelo vírus T Linfotrópico humano -1. No Brasil o vírus é endêmico, apresentando o maior número absoluto de casos no mundo e sendo incluído na triagem hematológica realizada nos hemocentros. As principais doenças associadas ao vírus T Linfotrópico humano -1 são a leucemia/linfoma de células T do adulto e a paraparesia espástica tropical. A única manifestação bucal associada ao vírus T Linfotrópico humano é o linfoma de células T do adulto, sendo que alguns autores apontam para a possibilidade de pacientes com paraparesia espástica tropical também apresentarem a síndrome de Sjõgren relacionada à infecção pelo vírus. O fato de o vírus T Linfotrópico humano ser um vírus contagioso e com capacidade oncogênica requer a atenção do cirurgião-dentista tanto no manejo odontológico quanto no diagnóstico de possíveis doenças associadas.

The human T-lymphotropic viruses represent a group of retroviruses that possess tropism for T lymphocytes and are transmitted parenterally, vertically and sexually. Four types have been identified, 1, 2, 3 and 4. Type 1 has been most frequently associated with disease in infected individuals. It is estimated that 15 to 20 million people are affected by human T-lymphotropic virus type 1. In Brazil, the virus is endemic, presenting the greatest absolute number of cases in the world and included in blood bank screening tests. The main diseases associated with human T-lymphotropic virus type 1 are adult T-cell leukemia/lymphoma and tropical spastic paraparesis. The only oral manifestation associated with human T-lymphotropic virus is adult T-cell lymphoma. Some authors believe it is possible for some patients with tropical spastic paraparesis to also present virus-related Sjõgren?s syndrome. Since human T-lymphotropic virus is contagious and potentially oncogenic, it demands attention from the dental surgeon not only for dental management but also for diagnosing associated diseases.

[HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study]. / Mielopatia associada ao HTLV-1: análise clínico-epidemiológica em uma série de casos de 10 anos.

INTRODUCTION: Human T cell lymphotropic virus type 1 (HTLV-I) myelopathy (HAM/TSP) is a progressive disabling disorder. This work aimed to analyze clinical features and epidemiology in a sample of HAM/TSP. METHODS: All HTLV-1 infected patients with diagnostic criteria for HAM/TSP, consecutively admitted to the Sarah Hospital from 1998 to 2007, were included in the study. RESULTS: 206 patients (67% females; mean age: 53.8 years-old) were diagnosed with HAM/TSP. The mean time of evolution was 9.0 years. The most common neurological symptoms were chronic progressive spastic paraparesis, spasticity, pain, neurogenic bladder and neurogenic bowel. The neurological findings were hyperreflexia, Babinsky, Hoffman and peripheral neuropathy. Pain, spasticity and spinal cord atrophy, observed in MRI, were associated with time of disease (p<0.05). CONCLUSIONS: HAM/TSP is a very disabling disorder, in which pain is reported early, while spasticity and thoracic spinal cord atrophy appear in a later phase of the disease. Cases of HAM/TSP exist with a probable vertical viral transmission.

Mielopatia associada ao HTLV-1: análise clínico-epidemiológica em uma série de casos de 10 anos / HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study

INTRODUÇÃO: A mielopatia associada ao retrovírus HTLV-1 (HAM/TSP) é uma doença progressiva e incapacitante. O objetivo deste trabalho é determinar características clínico-epidemiológicas de pacientes com HAM/TSP. MÉTODOS: Série de casos admitidos de 01/1998 a 12/ 2007, em hospital de reabilitação utilizando os critérios diagnósticos de HAM/TSP. RESULTADOS: Participaram 206 pacientes, dos quais, 67 por cento eram mulheres, com 53 anos de média de idade, nove anos de média de duração de doença. Os sintomas mais frequentes foram a diminuição da força em membros inferiores, espasticidade, dor, presença de bexiga neurogênica e a constipação intestinal. Os sinais neurológicos foram hiperreflexia, Babinsky, Hoffmann e neuropatia periférica. A presença de dor, de espasticidade muscular e de atrofia medular à ressonância nuclear magnética de medula espinhal foram associadas à duração da doença (p<0,05). CONCLUSÕES: A HAM/TSP é uma doença de curso incapacitante e progressiva, em que a dor é relatada precocemente, enquanto a atrofia medular torácica e a espasticidade surgem em fase mais tardia. Existem casos de HAM/TSP com provável transmissão do vírus por via vertical.

INTRODUCTION: Human T cell lymphotropic virus type 1 (HTLV-I) myelopathy (HAM/TSP) is a progressive disabling disorder. This work aimed to analyze clinical features and epidemiology in a sample of HAM/TSP. METHODS: All HTLV-1 infected patients with diagnostic criteria for HAM/TSP, consecutively admitted to the Sarah Hospital from 1998 to 2007, were included in the study. RESULTS: 206 patients (67 percent females; mean age: 53.8 years-old) were diagnosed with HAM/TSP. The mean time of evolution was 9.0 years. The most common neurological symptoms were chronic progressive spastic paraparesis, spasticity, pain, neurogenic bladder and neurogenic bowel. The neurological findings were hyperreflexia, Babinsky, Hoffman and peripheral neuropathy. Pain, spasticity and spinal cord atrophy, observed in MRI, were associated with time of disease (p<0.05). CONCLUSIONS: HAM/TSP is a very disabling disorder, in which pain is reported early, while spasticity and thoracic spinal cord atrophy appear in a later phase of the disease. Cases of HAM/TSP exist with a probable vertical viral transmission.

A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK.

BACKGROUND: The natural history of HTLV-1-associated myelopathy (HAM) has been mainly described in HTLV-1 endemic countries such as Japan, Brazil and Martinique. OBJECTIVES: The authors describe the natural history of the largest cohort of patients with HAM living in the UK from 1993 to 2007. METHODS: Prospective, longitudinal study comparing clinical and virological outcome between first and last clinical visit. Incidence and cause of death were documented and the mortality calculated. RESULTS: 48 patients were included: 79.2% were female, 79.2% were of Afro-Caribbean origin, and 83.3% acquired HTLV-1 through breastfeeding or unprotected heterosexual intercourse. The mean age of onset was 46 years. The median durations from onset of symptoms to diagnosis and to last follow-up were 2 and 11.6 years. The median time of follow-up was 3.8 years. The most common first recalled symptom was unilateral leg weakness. The median times from onset to unilateral, bilateral walking aid and frame or a wheelchair were 11, 11.2, 11.3 and 18 years. The overall average deterioration in timed walk in patients whose need for aid did not change was 2 s/10 m/year. Three patients progressed rapidly and were unable to walk within 2 years. Six patients were slow/non-progressors. The mortality was 2.4/100 person year follow-up. The median HTLV-1 viral load remained unchanged at 14%. CONCLUSIONS: HAM is a slowly progressing chronic disease. Timed walk deteriorates by 2 s/10 m/year, and patients remain ambulant for 10 years but become wheelchair-dependent a decade later. HTLV-1 viral load remains high and unchanged over time regardless of clinical progression.

Clinical studies on rising and re-rising neurological diseases in Japan--a personal contribution.

Throughout my research life, I experienced to discover the causes of some neurological diseases in Japan. 1) SMON (subacute myelo-optico-neuropathy). Since the early 1960s, a peculiar neurological disease became prevalent throughout Japan. Through the chemical analysis of the green urine, characteristic of this disease, it was found that this disease was caused by intoxication of the administered clioquinol, an anti-diarrheal drug. This discovery is a big topic in the history of Japanese medicine. 2) In early 1970s, I experienced many young patients with oedema and polyneuropathy in Kagoshima. Finally it was found that the disease was the long-forgotten beriberi, which had disappeared several decades ago. We must always be aware of beriberi even now, as far as we eat well-polished rice. 3) In 1972, we noticed a group of sporadic paraparesis in Kagoshima, which was 20 years later confirmed to be induced by human T lymphotropic virus type-I (HTLV-I). We named this disease as "HTLV-I associated myelopathy" (HAM). It gave a strong impact that the causative virus of adult T cell leukemia (ATL) can induce entirely different diseases, in terms of both the clinical course and the pathological features. It was also proven that HAM was identical with tropical spastic paraparesis, (TSP), which had been prevalent in many areas of tropical zones. These experiences are good examples of our slogan "to keep in mind to send message of scientific progress from the local area to the international stage.

[Case report of HTLV-1 associated myelopathy (HAM) manifested after renal transplantation].

We report a 51-year-old man with human T lymphotropic virus type-1 (HTLV-1) associated myelopathy (HAM) manifested 10 months after renal transplantation. He had progressive spastic paralysis and neurogenic bladder for 10 years. HTLV-1 antibody are positive both serum and cerebral spinal fluid (CSF). Althoght HTLV-1 was not examined in the donor, it was suspected that the patient was infected by renal transplantation. After treatment of interferon-alpha (IFN-alpha), his motor function had improved and neopterin in CSF was decreased from 158 pmol/ml to 89 pmol/ml. This is a rare case of HAM after living renal transplantation. Cyclosporin and methylpredonisolone are used as immunosuppressants for preventing graft rejection. Time for developing HAM after renal transplantation was shorter than patients after cadaveric renal transplantation. More investigations are needed to clarify the mechanisms in the development of HAM associated with renal transplantation.

Mielopatia associada ao HTLV-I: aspectos relacionados à infância / HTLV-I associated myelopathy: aspects related to childhood

A mielopatia associada ao HTLV-I ou paraparesia espástica tropical (HAM/TSP) é caracterizada por uma paraparesia espástica lentamente progressiva associada a disfunções esfincterianas e sensitivas. A enfermidade acomete indivíduos na faixa etária dos 30 aos 50 anos, sendo um diagnóstico negligenciado em crianças que se apresentam com paraparesia espástica de curso evolutivo. O presente estudo propõe uma revisão dos aspectos clínicos e epidemiológicos relacionados à HAM/TSP, suas principais formas de transmissão e os critérios para o diagnóstico em crianças com queixas neurológicas sugestivas.O conhecimento detalhado dos aspectos clínicos e laboratoriais que definem tal condição na infância e na adolescência contribui para o diagnóstico precoce desta enfermidade neurológica incapacitante.

The HTLV-I-associated myelopathy or tropical spastic paraparesis (HAM/TSP) is characterized by a slowly progressive spastic paraparesis associated with sphincter and sensory dysfunction. The disorder usually affects people aged from 30 to 50 years. This diagnosis is neglected by many clinicians in children who present with spastic paraparesis of progressive course. This study proposes a revision of clinical and epidemiological aspects related to HAM/TSP in children, their main mechanisms of transmission and the diagnosis criteria with suggestive neurological complaints. The detailed knowledge of clinical and laboratory that define this condition in childhood and adolescence will help to early diagnosis of this disabling neurological illness.

Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

The treatment of HAM/TSP is a challenge. No agent has shown to significantly modify the long-term disability associated with HAM/TSP. Advances in our understanding of the pathogenesis of HAM/TSP have led to the identification of several biomarkers and therapeutic targets. Clinical trials in HAM/TSP continue to be opportunities for further qualification and refinement of biomarkers and therapeutic targets. The validation of HAM/TSP relevant biomarkers and the identification of new targets remain key challenges in the development of effective targeted therapy in HAM/TSP.

Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Although human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is usually described as a chronic disabling disease, a rapid course over months or even weeks has been reported in some patients. The authors describe the clinical features of HAM/TSP in a Brazilian cohort and evaluate the prevalence of patients with a subacute progression of the disease. This was defined as the requirement of a wheelchair during the first 2 years after the onset of symptoms. Patients with this subacute course and patients with the chronic clinical course were compared in terms of their HTLV-I proviral loads (PLs) using real-time polymerase chain reaction (PCR). Seven out of 88 patients (7.9%) had a subacute progression. All patients were women and 5/7 acquired HTLV-I through sexual contact. There was no significant difference in the real-time PLs between the group with subacute evolution (mean 8.5 copies/100 cells, range 6.03 to 12.09) and those patients with a typical course of disease (mean 11.34 copies/100 cells, range 0.4 to 67.72) (P = .68), suggesting that factors other than the number of infected cells are implicated in the development of such an aggressive course of disease. Early recognition of this subgroup is important because immunosuppressive treatment might be beneficial if instituted promptly.

Human T cell lymphotropic virus type I (HTLV-I) p12I is dispensable for HTLV-I transmission and maintenance of infection in vivo.

The function of the p12(I) protein of human T cell lymphotropic virus type I (HTLV-I) has been under debate. p12K (lysine) and p12R (arginine) variants of this protein at amino acid 88 and a shorter life of p12K had been reported by another group. Because HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients usually have a higher provirus load than asymptomatic HTLV-I carriers (ACs), and p12(I) had been suggested to confer a proliferative effect on HTLV-I-infected cells in vitro, it is possible that the relatively unstable p12K is less frequent in HAM/TSP patients than in ACs. To elucidate whether p12K and other alterations in the p12 gene were related to the outcome of HTLV-I infection, we sequenced the p12 gene in 144 HAM/TSP patients, 41 adult T cell leukemia (ATL) patients, and in 46 ACs. p12K was observed in only two HAM/TSP patients, but was not present in either ATL patients or ACs. Interestingly, a premature termination codon in the p12 was observed in 5.6% of HAM/TSP patients and in 4.9% of ATL patients but none was found in ACs. The p12 initiation codon was destroyed in one HAM/TSP patient. These HTLV-I variants with truncated p12 protein or with a destroyed initiation codon in the p12 gene appeared to have been transmitted in the subjects' families. These findings suggest that p12 is dispensable for the transmission and maintenance of HTLV-I infection, although it is premature to conclude that sequence varitation in the p12 gene is associated with differences in the outcome of HTLV-I infection.

HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

To clarify clinical and laboratory findings that may be related to the pathomechanism of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), we analyzed these findings in 239 patients with HAM/TSP, including 64 patients followed up for 10 years after their first examinations, with special interest in the HTLV-I proviral load in peripheral blood mononuclear cells (PBMCs). The proviral load in PBMCs did not differ in terms of modes of HTLV-I transmission. However, the proviral load in patients with age of disease onset greater than 65 years tended to be higher than those with a younger age of onset. In the 64 patients followed up for 10 years, the clinical symptoms deteriorated in 36 patients (56%), unchanged in 26 patients (41%), and improved in 2 patients (3%). HTLV-I proviral load also appeared to be related to the deterioration of motor disability in these patients. To our knowledge, the present study is the first longitudinal study concerning the relationship between the clinical course of HAM/TSP and HTLV-I proviral load. It is suggested that HTLV-I proviral load is related to the progression of motor disability and is an important factor to predict prognosis of patients with HAM/TSP.